What is CRISPR Therapeutics's R&D?

CRISPR Therapeutics (CRSP) reported R&D of $68.57M in Q1 2026.

How has CRISPR Therapeutics's R&D changed year-over-year?

CRISPR Therapeutics's R&D decreased by 5.4% year-over-year, from $72.48M to $68.57M.

What is the long-term trend for CRISPR Therapeutics's R&D?

Over 4 years (2021 to 2025), CRISPR Therapeutics's R&D has grown at a -4.3% compound annual growth rate (CAGR), from $339.55M to $284.81M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

CRISPR Therapeutics CRSP R&D

R&D at other companies

Beam TherapeuticsBEAM

$104.52M+5.8%

Cogent Biosciences, Inc.COGT

$75.37M+19.6%

CelcuityCELC

$33.06M+11.1%

Arrowhead ResearchARWR

$173.25M+30.2%

Krystal Biotech, Inc.KRYS

$15.33M+7.5%

Spyre Therapeutics, Inc.SYRE

$60.41M+45.1%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's R&D?: CRISPR Therapeutics (CRSP) reported R&D of $68.57M in Q1 2026.
How has CRISPR Therapeutics's R&D changed year-over-year?: CRISPR Therapeutics's R&D decreased by 5.4% year-over-year, from $72.48M to $68.57M.
What is the long-term trend for CRISPR Therapeutics's R&D?: Over 4 years (2021 to 2025), CRISPR Therapeutics's R&D has grown at a -4.3% compound annual growth rate (CAGR), from $339.55M to $284.81M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.